The Long Run with Luke Timmerman
Ein Podcast von Timmerman Report
173 Folgen
-
Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Vom: 16.3.2025 -
Ep174: Najat Khan on the TechBio Movement
Vom: 3.3.2025 -
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Vom: 11.2.2025 -
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Vom: 27.1.2025 -
Ep171: Ram Aiyar on RNA Editing Medicines
Vom: 13.1.2025 -
Ep170: David Schenkein on Investing in the Future of Biotech
Vom: 2.1.2025 -
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Vom: 11.12.2024 -
Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer
Vom: 25.11.2024 -
Ep167: Leslie Williams on transfer RNA therapies
Vom: 6.11.2024 -
Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity
Vom: 15.10.2024 -
Ep165: Zach Hornby on Tackling Cancer Drug Resistance
Vom: 26.9.2024 -
Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients
Vom: 5.9.2024 -
Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases
Vom: 14.8.2024 -
Ep162: Sean McClain on AI for Biologic Drug Discovery
Vom: 16.7.2024 -
Ep161: Jeff Stein on a Long-Lasting Flu Drug
Vom: 1.7.2024 -
Ep160: Abe Ceesay on Precision Neuroscience
Vom: 17.6.2024 -
Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell Disease
Vom: 3.6.2024 -
Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery
Vom: 20.5.2024 -
Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery
Vom: 1.5.2024 -
Ep156: David Liu on New Tools and Techniques for Biology
Vom: 16.4.2024
"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
